

EMLc
ATC codes: V03AF01

<b>Indication</b>	Rhabdomyosarcoma primary site <span style="background-color: #00728f; color: white; padding: 2px 5px; border-radius: 5px; margin-left: 10px;">ICD11 code: <span style="color: yellow;">2C25.Z</span></span>
<b>INN</b>	Mesna
<b>Medicine type</b>	Chemical agent
<b>List type</b>	Complementary (EML) (EMLc)
<b>Additional notes</b>	*injection solution may also be used for oral administration.
<b>Formulations</b>	Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule ; 100 mg per mL in 2 mL ampoule Oral > Solid > tablet: 400 mg ; 600 mg
<b>EML status history</b>	First added in 2015 ( <span style="color: yellow;">TRS 994</span> ) Changed in 2025 ( <span style="color: yellow;">TRS 1064</span> )
<b>Sex</b>	All
<b>Age</b>	Also recommended for children
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <span style="color: yellow;">about patents.</span> 

**Tags** Cancer Cancer supportive care

**Wikipedia** Mesna 

**DrugBank** Mesna (Coenzyme M) 

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a 2 mL vial size of mesna solution for injection to the EML and EMLc. - the addition of a footnote indicating that the injection solution may also be used for oral administration.

Expert Committee report 

